Dengue, chikungunya, and Zika are diseases of major human concern. Differential diagnosis of these three diseases is ...

Azenta, Inc. ( NASDAQ: AZTA) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET John P. Marotta - President, CEO & Director Lawrence Y. Lin - Executive VP & CFO Yvonne Perron - Vice President ...

BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: refractory disease to first-line chemoimmunotherapy or relapse within 12 months of ...

Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne Year-over-year Q2 revenues ...

Balance Sheet: At June 30, 2025, Cumberland had approximately $68 million in total assets, including $16 million in cash and cash equivalents. Liabilities totaled $40 million, including $5 million on ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its second quarter ended June 30, 2025 and updated its ...

Secured First of its Kind Commercial Bank Loan Facility to Accelerate Nationwide Infrastructure Buildout <li /> $225 million oversubscrib ...

July with five participating lenders and option to increase up to $300 million.Record revenue of $98.0 million in the second quarter, representing ...